KR20030011275A - 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 - Google Patents
세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 Download PDFInfo
- Publication number
- KR20030011275A KR20030011275A KR1020027011630A KR20027011630A KR20030011275A KR 20030011275 A KR20030011275 A KR 20030011275A KR 1020027011630 A KR1020027011630 A KR 1020027011630A KR 20027011630 A KR20027011630 A KR 20027011630A KR 20030011275 A KR20030011275 A KR 20030011275A
- Authority
- KR
- South Korea
- Prior art keywords
- acetamide
- methyl
- methylpiperidin
- piperidin
- methylphenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
화합물 | 효능(평균) | 효능(stdev) | pIC50(평균) | pIC50(stdev) |
26HCH52 | 98 | 5.0 | 7.31 | 0.16 |
26HCH66-03 | 76 | 13.3 | 7.42 | 0.01 |
26HCH66-05 | 109 | 3.0 | 7.55 | 0.15 |
26HCH80-2 | 89 | 4.6 | 7.78 | 0.17 |
26HCH80-7 | 87 | 3.7 | 7.70 | 0.26 |
26HCH80-10 | 91 | 4.9 | 7.21 | 0.05 |
Claims (52)
- 하기 화학식(I)의 화합물:상기 식에서,Z는이며, 여기서 R은 수소, 시클릭 또는 직쇄 또는 분지형 아시클릭 오가닐(organyl) 그룹, 저급 히드록시알킬 그룹, 저급 아미노알킬 그룹, 또는 아랄킬 또는 헤테로아랄킬 그룹이고, n은 0, 1 또는 2 이고;X1은 메틸렌, 비닐렌, 또는 NH 또는 N(저급 알킬) 그룹이고;X2는 메틸렌이거나, X1이 메틸렌 또는 비닐렌인 경우 X2는 메틸렌 또는 단일결합이거나; X1이 메틸렌인 경우 X2는 O, S, NH 또는 N(저급 알킬) 또는 단일결합이고;Y1은 메틸렌이고, Y2는 메틸렌, 비닐렌, 에틸렌, 프로필렌 또는 단일결합이거나; Y1이 단일결합이고, Y2가 비닐렌이거나; Y1이 에틸렌이고, Y2가 O, S, NH 또는 N(저급 알킬)이고;Ar1및 Ar2는 독립적으로 치환되거나 치환되지 않은 아릴 또는 헤테로아릴 그룹이며, 단, Ar1및 Ar2는 동시에 페닐이 아니고;W는 산소 또는 황이다.
- 제 1항에 있어서, Y1이 메틸렌이고 Y2가 단일결합, 메틸렌, 에틸렌 또는 비닐렌이거나; Y1이 에틸렌이고 Y2가 O 또는 S 이고; X1이 메틸렌이고 X2가 단일결합, 메틸렌, O 또는 S 이거나; X1이 NH 또는 N(저급 알킬)이고 X2가 메틸렌임을 특징으로 하는 화합물.
- 제 2항에 있어서, Z가이고, W가 산소임을 특징으로 하는 화합물.
- 제 3항에 있어서, Ar1및 Ar2가 독립적으로 일치환되거나 이치환된 페닐 그룹임을 특징으로 하는 화합물.
- 제 4항에 있어서, R이 수소, 저급 알킬 그룹, 시클릭 오가닐 그룹, 또는 치환되거나 치환되지 않은 아랄킬 또는 헤테로아랄킬 그룹이고; n이 1이고; Y1이 메틸렌이고 Y2가 단일결합, 메틸렌, 에틸렌 또는 비닐렌이고; X1이 메틸렌이고 X2가 단일결합이거나; X1이 NH 또는 N(저급 알킬)이고 X2가 메틸렌이고; Ar1및 Ar2는 저급 알킬, 저급 알콕시 및 할로겐으로부터 선택된 그룹으로 독립적으로p-치환된 페닐 그룹임을 특징으로 하는 화합물.
- 제 1항에 있어서, 하기 화학식(II)를 지님을 특징으로 하는 화합물:상기 식에서, RN은 수소, 저급 알킬, 아랄킬 또는 헤테로아랄킬이고;ArL은 저급 알킬, 저급 알콕시 및 할로겐으로부터 선택되고;ArR은 저급 알킬, 저급 알콕시 및 할로겐으로부터 선택되고;k는 1 또는 2 이고;A-는 적합한 음이온이다.
- 제 1항에 있어서, 화합물이 하기 군으로부터 선택됨을 특징으로 하는 화합물:N-(1-(1-메틸에틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(2,2-디메틸에틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-펜틸피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-헥실피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-시클로헥실피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-시클로펜틸피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-시클로부틸피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-시클로프로필피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(시클로펜틸메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(시클로부틸메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(시클로프로필메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(2-히드록시에틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(3-히드록시프로필)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(피페리딘-4-일)-N'-페닐메틸카르바미드;N-((4-메틸페닐)메틸)-N-(1-(2-메틸프로필)피페리딘-4-일)-N'-페닐메틸카르바미드;N-(1-((2-브로모페닐)메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-N'-페닐메틸카르바미드;N-(1-((4-히드록시-3-메톡시페닐)메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-N'-페닐메틸카르바미드;N-(1-((5-에틸티엔-2-일)메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-N'-페닐메틸카르바미드;N-(1-(이미다졸-2-일메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-N'-페닐메틸카르바미드;N-(1-(시클로헥실메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-N'-페닐메틸카르바미드;N-(1-((4-플루오로페닐)메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-N'-페닐메틸카르바미드;N-((4-메틸페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-메틸피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((1-에틸피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-프로필피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((1-부틸피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(3,3-디메틸부틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-(시클로헥실메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-(2-메틸프로필)피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-((4-메틸페닐)메틸)피페리딘-4-일)-4-메톡시페닐아세트아미드;N-(1-((4-히드록시페닐)메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(1-((2-히드록시페닐)메틸)피페리딘-4-일)-N-((4-메틸페닐)메틸)-4-메톡시페닐아세트아미드;N-(3-페닐프로필)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-(2-페닐에틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((2-메톡시페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((2-클로로페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((3,4-디-메톡시페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((4-플루오로페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((2,4-디-클로로페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((3-메틸페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-((3-브로모페닐)메틸)-N-(피페리딘-4-일)-4-메톡시페닐아세트아미드;N-(1-(페닐메틸)피페리딘-4-일)-N-(3-페닐-2-프로펜-1-일)-4-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-3-페닐프로피온아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-(페닐티오)아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-페녹시아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-(4-클로로페녹시)아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-3-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-4-플루오로페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-2,5-디-메톡시페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-피페리딘-4-일)-4-클로로페닐아세트아미드;N-((4-메틸페닐)메틸)-N-(1-(페닐메틸)피롤리딘-3-일)-N'-페닐메틸카르바미드;N-((4-메틸페닐)메틸)-N-(1-(페닐메틸)피롤리딘-3-일)-4-메톡시페닐아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-(피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-(1-에틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-클로로벤질)-N-(1-에틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-클로로벤질)-N-(1-이소프로필피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-클로로벤질)-N-(피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-클로로벤질)-N-(1-시클로펜틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-클로로벤질)-N-(1-이소프로필피페리딘-4-일)아세트아미드;2-(페닐)-N-(4-트리플루오로메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-플루오로페닐)-N-(4-트리플루오로메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-트리플루오로메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-트리플루오로메틸페닐)-N-(4-트리플루오로메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-플루오로페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-트리플루오로메틸페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-트리플루오로메틸페닐)-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-페닐-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-클로로페닐)-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-트리플루오로메틸페닐)-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-페닐-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-클로로페닐)-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-[4-(메톡시카르보닐)벤질]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-[1-(4-클로로메틸-2-티아졸릴메틸)피페리딘-4-일]아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-{1-[3(1,3 디히드로-2H-벤즈이미다졸-2-온-1-일)프로필]피페리딘-4-일}아세트아미드;2-(4-메톡시페닐)-N-(2-4(플루오로페닐)에틸)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-[2-(2,5-디메톡시페닐)에틸]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-[2-(2,4-디클로로페닐)에틸]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-[2-(3-클로로페닐)에틸]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-[2-(4-메톡시페닐)에틸]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-[2-(3-플루오로페닐)에틸]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-에톡시페닐)-N-[2-(4-플루오로페네틸]-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-에톡시페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-{1-[2-(2-히드록시에톡시)에틸]피페리딘-4-일}아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-{1-((2-클로로-5-티에닐)메틸)피페리딘-4-일}아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-[1-(2-(이미다졸리디논-1-일)에틸)피페리딘-4-일]아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-{1-[2-(2,4(1H,3H)퀴나졸린디온-3-일)에틸]피페리딘-4-일}아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-{1-[2-(1,3-디옥솔란-2-일)에틸]피페리딘-4-일}아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-{1-[2-(3-인돌릴)에틸]피페리딘-4-일}아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-{1-[3-(1,2,4-트리아졸-1-일)프로필]피페리딘-4-일}아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-[1-(5-벤조푸라자닐메틸)피페리딘-4-일]아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-[1-(5-클로로벤조[b]티엔-3-일메틸)피페리딘-4-일]아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-[1-(5-페닐-1,2,4-옥사디아졸-3-일메틸)피페리딘-4-일]아세트아미드;2-(4-클로로페닐)-N-(4-메틸벤질)-N-(1-이소프로필피페리딘-4-일)-아세트아미드;2-(4-클로로페닐)-N-(4-메틸벤질)-N-(1-에틸피페리딘-4-일)-아세트아미드;2-페닐-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드,2-(4-클로로페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;2-(4-클로로페닐)-N-(4-메틸벤질)-N-(1-시클로펜틸피페리딘-4-일)-아세트아미드;2-(4-플루오로페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;2-(4-클로로페닐)-N-(4-메틸벤질)-N-(1-(2-히드록시에틸)-피페리딘-4-일)-아세트아미드;2-(4-클로로페닐)-N-(4-메틸벤질)-N-(1-시클로부틸피페리딘-4-일)-아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-(1-시클로부틸피페리딘-4-일)-아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-(트로핀-4-일)-아세트아미드;N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-N'-벤질-카르바미드;N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-N'-페닐-카르바미드;N-페네틸-N-(1-메틸피페리딘-4-일)-N'-벤질-카르바미드;2-페닐-N-(4-메톡시벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;2-(4-트리플루오로메틸페닐)-N-(4-메톡시벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;2-(4-플루오로페닐)-N-(4-메톡시벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;2-(4-메톡시페닐)-N-(4-메톡시벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;2-(4-메틸페닐)-N-(4-클로로벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;2-(4-히드록시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-아세트아미드;N-페네틸-N-(1-메틸피페리딘-4-일)-N'-페닐-카르바미드;N-(3-페닐프로필)-N-(1-메틸피페리딘-4-일)-N'-벤질-카르바미드;N-(3-페닐프로필)-N-(1-메틸피페리딘-4-일)-N'-페닐-카르바미드;2-(4-메톡시페닐)-2,2-에틸렌-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-알파-메틸벤질-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-(3-트로펜-4-일)아세트아미드;2-페닐-2-에틸-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;N-페네틸-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-아민;2-(4-메톡시페닐)-N-(1-인다닐)-N-(1-메틸피페리딘-4-일)아세트아미드;N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-N'-(4-메톡시벤질)-카르바미드;2-(3,4-디메톡시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(3,4-메틸렌디옥시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-메톡시페닐)-N-(4-메틸벤질)-N-(1-t-부틸피페리딘-4-일)아세트아미드;N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)-N'-페네틸-카르바미드;N-페네틸-N-(1-메틸피페리딘-4-일)-N'-페네틸-카르바미드;N-(4-메틸벤질)-N-(1-t-부틸피페리딘-4-일)-N'-(4-메톡시벤질)-카르바미드;2-(4-에톡시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-부톡시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-i-프로폭시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-t-부톡시페닐)-N-(4-메틸벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-부톡시페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-프로폭시페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드;2-(4-i-프록폭시페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드; 및2-(4-t-부톡시페닐)-N-(4-플루오로벤질)-N-(1-메틸피페리딘-4-일)아세트아미드.
- 하기 화학식(I)의 화합물:상기 식에서,Z는이고, 여기서 R은 수소, 시클릭 또는 직쇄 또는 분지형 아시클릭 오가닐 그룹, 저급 히드록시알킬 그룹, 저급 아미노알킬 그룹, 또는 아랄킬 또는 헤테로아랄킬 그룹이며, n은 0, 1 또는 2 이고;X1은 메틸렌, 비닐렌, 또는 NH 또는 N(저급 알킬) 그룹이고;X2는 메틸렌이거나, X1이 메틸렌 또는 비닐렌인 경우 X2는 메틸렌 또는 단일결합이거나; X1이 메틸렌인 경우 X2는 O, S, NH 또는 N(저급 알킬) 또는 단일결합이고;Y1은 메틸렌이고, Y2는 메틸렌, 비닐렌, 에틸렌, 프로필렌 또는 단일결합이거나; Y1이 단일결합이고, Y2가 비닐렌이거나; Y1이 에틸렌이고, Y2가 O, S, NH 또는N(저급 알킬)이고;Ar1및 Ar2는 상이한 치환되거나 치환되지 않은 아릴 또는 헤테로아릴 그룹이고;W는 산소 또는 황이다.
- 제 8항에 있어서, Y1이 메틸렌이고 Y2가 단일결합, 메틸렌, 에틸렌 또는 비닐렌이거나; Y1이 에틸렌이고 Y2가 O 또는 S 이고; X1이 메틸렌이고 X2가 단일결합, 메틸렌, O 또는 S 이거나; X1이 NH 또는 N(저급 알킬)이고 X2가 메틸렌임을 특징으로 하는 화합물.
- 제 9항에 있어서, Z가이고, W가 산소임을 특징으로 하는 화합물.
- 제 10항에 있어서, Ar1및 Ar2가 독립적으로 일치환되거나 이치환된 페닐 그룹임을 특징으로 하는 화합물.
- 제 11항에 있어서, R이 수소, 저급 알킬 그룹, 시클릭 오가닐 그룹, 또는 치환되거나 치환되지 않은 아랄킬 또는 헤테로아랄킬 그룹이고;n이 1 이고;Y1이 메틸렌이고, Y2가 단일결합, 메틸렌, 에틸렌 또는 비닐렌이고;X1이 메틸렌이고 X2가 단일결합이거나, X1이 NH 또는 N(저급 알킬) 이고 X2가 메틸렌이고;Ar1및 Ar2가 알킬, 저급 알콕시 및 할로겐으로부터 선택된 그룹으로 독립적으로 p-치환된 페닐 그룹임을 특징으로 하는 화합물.
- 제 7항에 있어서, 하기 화학식(II)를 지님을 특징으로 하는 화합물:상기 식에서, RN은 수소, 저급 알킬, 아랄킬 또는 헤테로아랄킬이고;ArL은 저급 알킬, 저급 알콕시 및 할로겐으로부터 선택되고;ArR은 저급 알킬, 저급 알콕시 및 할로겐으로부터 선택되고;k는 1 또는 2 이고,A-는 적합한 음이온이다.
- 유효량의 하기 화학식(I)의 화합물 또는 이의 약제학적으로 허용되는 염, 에스테르 또는 프로드러그, 및 약제학적으로 허용되는 희석제 또는 부형제를 포함하는 약제학적 조성물:상기 식에서,Z는이며, 여기서 R은 수소, 시클릭 또는 직쇄 또는 분지형 아시클릭 오가닐 그룹, 저급 히드록시알킬 그룹, 저급 아미노알킬 그룹, 또는 아랄킬 또는 헤테로아랄킬 그룹이고, n은 0, 1 또는 2 이고;X1은 메틸렌, 비닐렌, 또는 NH 또는 N(저급 알킬) 그룹이고;X2는 메틸렌이거나, X1이 메틸렌 또는 비닐렌인 경우 X2는 메틸렌 또는 단일결합이거나; X1이 메틸렌인 경우 X2는 O, S, NH 또는 N(저급 알킬) 또는 단일결합이고;Y1은 메틸렌이고, Y2는 메틸렌, 비닐렌, 에틸렌, 프로필렌 또는 단일결합이거나; Y1이 단일결합이고, Y2가 비닐렌이거나; Y1이 에틸렌이고, Y2가 O, S, NH 또는 N(저급 알킬)이고;Ar1및 Ar2는 독립적으로 치환되거나 치환되지 않은 아릴 또는 헤테로아릴 그룹이며, 단, Ar1및 Ar2는 동시에 페닐이 아니고;W는 산소 또는 황이다.
- 모노아민 수용체 또는 모노아민 수용체를 함유하는 시스템을 모노아민 수용체의 활성을 억제하기에 유효한 양의 1종 이상의 제 1항의 화합물과 접촉시키는 것을 포함하여, 모노아민 수용체의 활성을 억제하는 방법.
- 제 15항에 있어서, 모노아민 수용체가 세로토닌 수용체임을 특징으로 하는 방법.
- 제 16항에 있어서, 세로토닌 수용체가 5-HT2A 서브클래스임을 특징으로 하는 방법.
- 제 16항에 있어서, 세로토닌 수용체가 중추 신경계에 존재함을 특징으로 하는 방법.
- 제 16항에 있어서, 세로토닌 수용체가 말초 신경계에 존재함을 특징으로 하는 방법.
- 제 16항에 있어서, 세로토닌 수용체가 혈구 또는 혈소판에 존재함을 특징으로 하는 방법.
- 제 16항에 있어서, 세로토닌 수용체가 돌연변이되거나 변형됨을 특징으로 하는 방법.
- 제 15항에 있어서, 활성이 시그널링 활성임을 특징으로 하는 방법.
- 제 15항에 있어서, 활성이 구성적(constitutive)임을 특징으로 하는 방법.
- 제 15항에 있어서, 활성이 세로토닌 수용체 활성화와 관련됨을 특징으로 하는 방법.
- 모노아민 수용체 또는 모노아민 수용체를 함유하는 시스템을 모노아민 수용체의 활성화를 억제하기에 유효한 양의 1종 이상의 제 1항의 화합물과 접촉시키는 것을 포함하여, 모노아민 수용체의 활성화를 억제하는 방법.
- 제 25항에 있어서, 활성화가 아고니스틱(agonistic) 작용제에 의해 일어남을 특징으로 하는 방법.
- 제 26항에 있어서, 아고니스틱 작용제가 외인성임을 특징으로 하는 방법.
- 제 26항에 있어서, 아고니스틱 작용제가 내인성임을 특징으로 하는 방법.
- 제 25항에 있어서, 활성화가 구성적임을 특징으로 하는 방법.
- 제 25항에 있어서, 모노아민 수용체가 세로토닌 수용체임을 특징으로 하는 방법.
- 제 30항에 있어서, 세로토닌 수용체가 5-HT2A 서브클래스임을 특징으로 하는 방법.
- 제 30항에 있어서, 세로토닌 수용체가 중추 신경계에 존재함을 특징으로 하는 방법.
- 제 30항에 있어서, 세로토닌 수용체가 말초 신경계에 존재함을 특징으로 하는 방법.
- 제 30항에 있어서, 세로토닌 수용체가 혈구 또는 혈소판에 존재함을 특징으로 하는 방법.
- 제 30항에 있어서, 세로토닌 수용체가 돌연변이되거나 변형됨을 특징으로 하는 방법.
- 치료적 유효량의 1종 이상의 제 1항의 화합물을 치료가 필요한 피검자에게 투여하는 것을 포함하여, 모노아민 수용체와 관련된 질환을 치료하는 방법.
- 제 36항에 있어서, 질환이 정신분열증, 정신병, 편두통, 고혈압, 혈전증, 혈관경련, 허혈, 우울증, 불안, 수면장애 및 식욕장애로 구성된 군으로부터 선택됨을 특징으로 하는 방법.
- 제 36항에 있어서, 질환이 모노아민 수용체의 기능부전과 관련됨을 특징으로 하는 방법.
- 제 36항에 있어서, 질환이 모노아민 수용체의 활성화와 관련됨을 특징으로 하는 방법.
- 제 36항에 있어서, 질환이 모노아민 수용체의 활성 증가와 관련됨을 특징으로 하는 방법.
- 제 36항에 있어서, 모노아민 수용체가 세로토닌 수용체임을 특징으로 하는 방법.
- 제 41항에 있어서, 세로토닌 수용체가 5-HT2A 서브클래스임을 특징으로 하는 방법.
- 제 41항에 있어서, 세로토닌 수용체가 중추 신경계에 존재함을 특징으로 하는 방법.
- 제 41항에 있어서, 세로토닌 수용체가 말초 신경계에 존재함을 특징으로 하는 방법.
- 제 41항에 있어서, 세로토닌 수용체가 혈구 또는 혈소판에 존재함을 특징으로 하는 방법.
- 제 41항에 있어서, 세로토닌 수용체가 돌연변이되거나 변형됨을 특징으로 하는 방법.
- 치료적 유효량의 1종 이상의 제 1항의 화합물을 치료가 필요한 피검자에게 투여하는 것을 포함하여, 정신분열증을 치료하는 방법.
- 치료적 유효량의 1종 이상의 제 1항의 화합물을 치료가 필요한 피검자에게 투여하는 것을 포함하여, 편두통을 치료하는 방법.
- 치료적 유효량의 1종 이상의 제 1항의 화합물을 치료가 필요한 피검자에게 투여하는 것을 포함하여, 정신병을 치료하는 방법.
- 피검자에게 치료적 유효량의 제 1항의 화합물을 투여하고;상기 화합물에 대한 피검자의 반응을 측정하여 모노아민 수용체와 관련된 질환의 개선을 나타내는 반응성 피검자를 확인하고;피검자가 상기 화합물에 반응성이 되도록 하는 유전적 다형성을 반응성 피검자에게서 확인하는 것을 포함하여, 피검자가 1종 이상의 제 1항의 화합물에 반응성이 되도록 하는 유전적 다형성을 확인하는 방법.
- 제 50항에 있어서, 질환 개선이 모노아민성 수용체의 5-HT 클래스 또는 5-HT2A 서브클래스와 관련됨을 특징으로 하는 방법.
- 피검자가 제 1항의 화합물에 반응성이 되도록 하는 다형성이 피검자에 존재하는 지를 검출하는 것을 포함하여 1종 이상의 제 1항의 화합물로 치료하기에 적합한 피검자를 확인하는 방법으로서, 다형성의 존재가 피검자가 1종 이상의 제 1항의 화합물로 치료하기에 적합함을 나타내는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18728900P | 2000-03-06 | 2000-03-06 | |
US60/187,289 | 2000-03-06 | ||
PCT/US2001/007187 WO2001066521A1 (en) | 2000-03-06 | 2001-03-06 | Azacyclic compounds for use in the treatment of serotonin related diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087015236A Division KR20080059687A (ko) | 2000-03-06 | 2001-03-06 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030011275A true KR20030011275A (ko) | 2003-02-07 |
KR100879647B1 KR100879647B1 (ko) | 2009-01-20 |
Family
ID=22688370
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087015236A KR20080059687A (ko) | 2000-03-06 | 2001-03-06 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
KR1020027011630A KR100879647B1 (ko) | 2000-03-06 | 2001-03-06 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087015236A KR20080059687A (ko) | 2000-03-06 | 2001-03-06 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
Country Status (21)
Country | Link |
---|---|
US (9) | US6815458B2 (ko) |
EP (1) | EP1263729B1 (ko) |
JP (1) | JP4664564B2 (ko) |
KR (2) | KR20080059687A (ko) |
CN (2) | CN1443167B (ko) |
AT (1) | ATE348808T1 (ko) |
AU (2) | AU780006B2 (ko) |
BR (1) | BRPI0108977B8 (ko) |
CA (1) | CA2397981C (ko) |
CY (1) | CY1118651T1 (ko) |
DE (1) | DE60125335T2 (ko) |
DK (2) | DK1787984T3 (ko) |
ES (1) | ES2278729T3 (ko) |
HK (1) | HK1051684A1 (ko) |
IL (2) | IL151164A0 (ko) |
MX (1) | MXPA02008770A (ko) |
NZ (1) | NZ520240A (ko) |
PT (1) | PT1263729E (ko) |
RU (3) | RU2002126554A (ko) |
WO (1) | WO2001066521A1 (ko) |
ZA (1) | ZA200205902B (ko) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
JP4664564B2 (ja) * | 2000-03-06 | 2011-04-06 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン関連疾患の治療に使用する含窒素環式化合物 |
JP2004509103A (ja) * | 2000-09-11 | 2004-03-25 | セプレイコー インコーポレイテッド | モノアミン受容体及び輸送体のリガンドならびにその使用方法 |
BR0113989A (pt) * | 2000-09-25 | 2004-01-27 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos |
US6693099B2 (en) * | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
JP2005508872A (ja) * | 2001-05-23 | 2005-04-07 | ニューロサーチ、アクティーゼルスカブ | トロパン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法 |
US6951849B2 (en) * | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
US7087593B2 (en) * | 2001-10-02 | 2006-08-08 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
EP1461339B1 (en) | 2001-12-28 | 2010-04-28 | Acadia Pharmaceuticals Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
AU2007203444C1 (en) * | 2002-06-24 | 2010-03-11 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
NZ537522A (en) * | 2002-06-24 | 2006-07-28 | Acadia Pharm Inc | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004009549A2 (en) * | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
SG170617A1 (en) | 2003-01-16 | 2011-05-30 | Acadia Pharm Inc | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
KR20060006069A (ko) * | 2003-04-30 | 2006-01-18 | 액테리온 파마슈티칼 리미티드 | 아자비사이클로노넨 유도체 |
WO2005000811A1 (en) * | 2003-06-11 | 2005-01-06 | Eli Lilly And Company | 3-aminopyrrolidines as inhibitors of monoamine uptake |
CA2530159C (en) * | 2003-06-17 | 2010-02-02 | Pfizer Inc. | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
AU2004283814A1 (en) * | 2003-10-09 | 2005-05-06 | Actelion Pharmaceuticals Ltd. | Tetrahydropyridine derivatives |
JP2007508262A (ja) * | 2003-10-13 | 2007-04-05 | アクテリオン ファマシューティカルズ リミテッド | 新規ジアザビシクロノネン誘導体およびその使用 |
US7321042B2 (en) * | 2003-10-16 | 2008-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing N-substituted 3-β-aminonortropanes |
DE102004013227A1 (de) * | 2004-03-18 | 2005-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von N-Substituierten 3-Beta-Aminonortropanen |
CA2540817A1 (en) * | 2003-10-23 | 2005-05-06 | Olivier Bezencon | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
WO2005053663A2 (en) * | 2003-11-24 | 2005-06-16 | Eli Lilly And Company | Norepinephrine reuptake inhibitors useful for treatment of cognitive failure |
US7588733B2 (en) * | 2003-12-04 | 2009-09-15 | Idexx Laboratories, Inc. | Retaining clip for reagent test slides |
US20070111989A1 (en) * | 2003-12-05 | 2007-05-17 | Olivier Bezencon | Novel diazabicyclononene derivatives and use |
US20070135406A1 (en) * | 2003-12-05 | 2007-06-14 | Olivier Bezencon | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain |
WO2005060968A1 (en) | 2003-12-11 | 2005-07-07 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
WO2006037043A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2006064332A1 (en) * | 2004-12-14 | 2006-06-22 | Pfizer Limited | N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
US20060173037A1 (en) * | 2005-01-10 | 2006-08-03 | Nathalie Schlienger | Aminophenyl derivatives as selective androgen receptor modulators |
WO2007124136A1 (en) * | 2006-04-19 | 2007-11-01 | Acadia Pharmaceuticals, Inc. | Use of 4-amino-piperidines for treating sleep disorders |
CN101511793B (zh) * | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
ATE511396T1 (de) | 2007-02-28 | 2011-06-15 | Thromboserin Ltd | Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko |
JP2010522198A (ja) | 2007-03-19 | 2010-07-01 | アカドイア プハルマセウチカルス インコーポレーテッド | 5−ht2aインバースアゴニスト及びアンタゴニストの抗精神病薬との併用 |
CA2700332A1 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
DK2200610T3 (en) * | 2007-09-21 | 2018-04-23 | Acadia Pharm Inc | ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS |
MX2010013192A (es) * | 2008-06-16 | 2010-12-17 | Hoffmann La Roche | Monoamidas heteroaromaticas como antagonistas de receptor orexinina. |
WO2010111353A1 (en) * | 2009-03-25 | 2010-09-30 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
WO2012113103A1 (en) * | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
WO2014085362A1 (en) | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
KR20160079846A (ko) * | 2013-11-27 | 2016-07-06 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 피페리딘 및 피페라진 유도체, 및 바이러스 감염 및 암 치료에서의 그의 용도 |
US10597363B2 (en) | 2015-07-20 | 2020-03-24 | Acadia Pharmaceuticals Inc. | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C |
CN105153016B (zh) * | 2015-10-12 | 2017-10-03 | 北京诺康达医药科技有限公司 | 一种匹莫范色林的制备方法 |
CN105906531A (zh) * | 2015-12-23 | 2016-08-31 | 嘉实(湖南)医药科技有限公司 | 一种匹莫范色林中间体的制备方法 |
CN105481757A (zh) * | 2015-12-25 | 2016-04-13 | 北京康立生医药技术开发有限公司 | 一种哌马色林的制备方法 |
CN105523993A (zh) * | 2015-12-28 | 2016-04-27 | 重庆两江药物研发中心有限公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用 |
CA3017048C (en) | 2016-03-22 | 2023-11-07 | Helsinn Healthcare Sa | Benzenesulfonyl-asymmetric ureas and medical uses thereof |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
WO2019040104A2 (en) * | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES |
BR112020003477A2 (pt) | 2017-08-21 | 2020-08-25 | Acadia Pharmaceuticals, Inc. | compostos e método para tratar uma doença |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
US10781172B2 (en) | 2018-06-21 | 2020-09-22 | Northwestern University | Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles |
US20220016101A1 (en) | 2018-10-30 | 2022-01-20 | Acadia Pharmaceuticals Inc. | Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin |
CN113214141B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其制备和应用 |
CN113214231B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其医疗应用 |
CN116730981A (zh) * | 2020-07-22 | 2023-09-12 | 山东绿叶制药有限公司 | 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用 |
CN114763335A (zh) * | 2021-01-15 | 2022-07-19 | 江苏谛奇医药科技有限公司 | 4-酰胺哌啶类衍生物及其制备方法和应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1234567A (en) * | 1915-09-14 | 1917-07-24 | Edward J Quigley | Soft collar. |
BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
GB1507462A (en) * | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
GB1586468A (en) * | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
CA1140119A (en) | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
US4255432A (en) * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4332804A (en) * | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
FR2642069B1 (fr) * | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5214055A (en) * | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
US5216165A (en) * | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
AU6971794A (en) | 1993-05-26 | 1994-12-20 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
DE4404183A1 (de) * | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
JPH11512723A (ja) | 1995-09-29 | 1999-11-02 | イーライ リリー アンド カンパニー | フィブリノゲン依存血小板凝集抑制物質としてのスピロ化合物 |
US5891889A (en) * | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2001519766A (ja) * | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
ATE269312T1 (de) * | 1996-04-17 | 2004-07-15 | Bristol Myers Squibb Pharma Co | N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren |
US5869488A (en) * | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
CZ82399A3 (cs) | 1996-09-10 | 1999-06-16 | Dr. Karl Thomae Gmbh | Modifikované aminokyseliny, způsob jejich výroby a farmaceutický prostředek s jejich obsahem |
DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
CN1255162A (zh) | 1997-05-08 | 2000-05-31 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
ES2156845T1 (es) | 1998-04-14 | 2001-08-01 | Arena Pharm Inc | Receptores de serotonina humana no endogenos constitutivamente activados y moduladores de moleculas pequeñas para estos. |
US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6358698B1 (en) * | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
WO2000020636A1 (en) * | 1998-10-07 | 2000-04-13 | Acadia Pharmaceuticals Inc. | Methods of identifying inverse agonists of the serotonin 2a receptor |
ES2221440T3 (es) | 1998-10-16 | 2004-12-16 | Daiichi Suntory Pharma Co Ltd | Derivados de acido aminofenoxiacetico como neuroprotectores. |
US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
WO2000056335A1 (en) | 1999-03-24 | 2000-09-28 | The Regents Of The University Of California | Methods for treating neurodegenerative disorders using aspartyl protease inhibitors |
US6399619B1 (en) * | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
ES2250128T3 (es) | 1999-05-17 | 2006-04-16 | Novo Nordisk A/S | Antagonistas/agonistas inversos de glucagon. |
US20050148018A1 (en) * | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) * | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
JP3700524B2 (ja) * | 2000-03-03 | 2005-09-28 | 株式会社村田製作所 | 多層集合基板および多層セラミック部品の製造方法 |
JP4664564B2 (ja) * | 2000-03-06 | 2011-04-06 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン関連疾患の治療に使用する含窒素環式化合物 |
GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
EP1461339B1 (en) | 2001-12-28 | 2010-04-28 | Acadia Pharmaceuticals Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
NZ537522A (en) * | 2002-06-24 | 2006-07-28 | Acadia Pharm Inc | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004009549A2 (en) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
AU2003284899A1 (en) | 2002-10-29 | 2004-05-25 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
SG170617A1 (en) * | 2003-01-16 | 2011-05-30 | Acadia Pharm Inc | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
BRPI0406592A (pt) | 2003-01-23 | 2005-12-20 | Acadia Pharm Inc | Usos de n-desmetilclozapina, métodos para o tratamento de psicose, de distúrbios afetivos, de demência, de dor neuropática e de glaucoma e composição farmacêutica |
CN100372838C (zh) | 2003-02-17 | 2008-03-05 | 弗·哈夫曼-拉罗切有限公司 | 哌啶-苯磺酰胺衍生物 |
KR101157881B1 (ko) | 2003-12-22 | 2012-07-06 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 작용제로서의 아미노 치환된 디아릴[a,d]사이클로헵텐 유사체, 및 신경정신 질환의 치료 방법 |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
WO2006037043A1 (en) * | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
US7732167B2 (en) * | 2005-06-17 | 2010-06-08 | Regeneron Pharmaceuticals, Inc. | Interferon-α/β binding fusion proteins and therapeutic uses thereof |
-
2001
- 2001-03-06 JP JP2001565339A patent/JP4664564B2/ja not_active Expired - Lifetime
- 2001-03-06 DK DK06026352.2T patent/DK1787984T3/en active
- 2001-03-06 IL IL15116401A patent/IL151164A0/xx unknown
- 2001-03-06 WO PCT/US2001/007187 patent/WO2001066521A1/en active IP Right Grant
- 2001-03-06 ES ES01914716T patent/ES2278729T3/es not_active Expired - Lifetime
- 2001-03-06 BR BRPI0108977A patent/BRPI0108977B8/pt not_active IP Right Cessation
- 2001-03-06 DE DE60125335T patent/DE60125335T2/de not_active Expired - Lifetime
- 2001-03-06 RU RU2002126554/04A patent/RU2002126554A/ru not_active Application Discontinuation
- 2001-03-06 KR KR1020087015236A patent/KR20080059687A/ko not_active Application Discontinuation
- 2001-03-06 CN CN018061265A patent/CN1443167B/zh not_active Expired - Lifetime
- 2001-03-06 AT AT01914716T patent/ATE348808T1/de active
- 2001-03-06 EP EP01914716A patent/EP1263729B1/en not_active Expired - Lifetime
- 2001-03-06 PT PT01914716T patent/PT1263729E/pt unknown
- 2001-03-06 DK DK01914716T patent/DK1263729T3/da active
- 2001-03-06 AU AU40072/01A patent/AU780006B2/en not_active Ceased
- 2001-03-06 CN CNA2007101369494A patent/CN101230034A/zh active Pending
- 2001-03-06 CA CA2397981A patent/CA2397981C/en not_active Expired - Lifetime
- 2001-03-06 KR KR1020027011630A patent/KR100879647B1/ko active IP Right Grant
- 2001-03-06 NZ NZ520240A patent/NZ520240A/en not_active IP Right Cessation
- 2001-03-06 MX MXPA02008770A patent/MXPA02008770A/es active IP Right Grant
- 2001-03-06 US US09/800,096 patent/US6815458B2/en not_active Expired - Lifetime
- 2001-03-06 RU RU2009104112/04A patent/RU2398765C1/ru active
-
2002
- 2002-07-23 ZA ZA200205902A patent/ZA200205902B/en unknown
- 2002-08-09 IL IL151164A patent/IL151164A/en active IP Right Grant
-
2003
- 2003-04-07 US US10/409,782 patent/US6756393B2/en not_active Expired - Lifetime
- 2003-05-31 HK HK03103893A patent/HK1051684A1/xx not_active IP Right Cessation
-
2004
- 2004-03-16 US US10/802,970 patent/US20050014757A1/en not_active Abandoned
-
2005
- 2005-05-24 AU AU2005202257A patent/AU2005202257C1/en not_active Expired
-
2006
- 2006-05-03 US US11/417,790 patent/US20060194778A1/en not_active Abandoned
- 2006-05-03 US US11/417,782 patent/US20060194834A1/en not_active Abandoned
-
2007
- 2007-10-29 RU RU2007139896/04A patent/RU2007139896A/ru unknown
-
2009
- 2009-01-16 US US12/355,737 patent/US20090186921A1/en not_active Abandoned
-
2011
- 2011-03-21 US US13/053,079 patent/US9765053B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 US US14/628,156 patent/US9296694B2/en not_active Expired - Fee Related
-
2016
- 2016-02-16 US US15/045,064 patent/US20160237036A1/en not_active Abandoned
-
2017
- 2017-01-18 CY CY20171100069T patent/CY1118651T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100879647B1 (ko) | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 | |
KR101519682B1 (ko) | 4급 오피오이드 카르복스아미드 | |
AU2003248590A1 (en) | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | |
AU2009308854A1 (en) | Analgesic that binds filamin A | |
TW200843743A (en) | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin S | |
PL184489B1 (pl) | Nowa N acylo podstawiona benzimidazolilo lub imidazopirydynylo podstawiona piperydyna kompozycja farmaceutyczna sposób wytwarzania kompozycji farmaceutycznej i sposób wytwarzania N acylo podstawionej benzimidazolilo lub imidazopiperydynylo podstawionej piperydyny | |
JP2674199B2 (ja) | 二環式アミン化合物およびその製造法 | |
DE60112725T2 (de) | Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors | |
JP2009523747A (ja) | α7ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用 | |
EP1787984B1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121227 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131226 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141226 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151228 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161230 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171229 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 11 |